U.S. Pharmacopeia Drops Biologics Naming Proposal
Citing concerns among stakeholders including the FDA, the U.S. Pharmacopeia decided not to move forward with proposed revisions to its nomenclature for biologics.
Source: Drug Industry Daily
Citing concerns among stakeholders including the FDA, the U.S. Pharmacopeia decided not to move forward with proposed revisions to its nomenclature for biologics.
Source: Drug Industry Daily